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Despite the frequency of cardiovascular death in dialysis
patients, few studies have prospectively measured sudden
cardiac death in these individuals. Here, we sought to
determine the frequency of sudden cardiac death and its
association with inflammation and other risk factors among
the CHOICE (Choices for Healthy Outcomes In Caring for
ESRD) cohort of 1,041 incident dialysis patients. Sudden
cardiac death was defined as that occurring outside of the
hospital with an underlying cardiac cause from death
certificate data. Over a median 2.5 years of follow-up, 22% of
all mortality in this cohort was due to sudden cardiac death.
Using Cox proportional hazards, we found that the highest
tertiles of high-sensitivity C-reactive protein and of IL-6 were
each associated with twice the risk of sudden cardiac death
compared to their lowest tertiles when adjusted for
demographics, comorbidities and laboratory factors.
A decrement in serum albumin was associated with a 1.35
times increased risk for sudden cardiac death in the highest
compared to the lowest tertile. These findings were robust
and consistent when accounting for competing risks of death
from other causes. Hence, we found that sudden cardiac
death is common among patients with end stage renal
disease and that inflammation and malnutrition significantly
increased its occurrence independent of traditional
cardiovascular risk factors.
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Persons in the United States with treated end-stage renal
disease (ESRD) have an annual mortality rate of over 20%
and death rates from cardiovascular disease (CVD) that are
10–100 times higher than the general population, depending
on age.1 Sudden cardiac death (SCD) is a common
manifestation of coronary artery disease in the general
population. SCD is manifested by a cardiac arrest due to fatal
arrhythmias triggered either by coronary ischemia or other
nonischemic mechanisms. On the basis of administrative
data, the incidence of death from cardiac arrest, or
arrhythmia is high in ESRD patients, approximately 22% of
all deaths and the incidence increases with age (20 per 1000
patient-years for ages 20–44 years, 37 for ages 45–64 years,
and 69.5 for ages 65 years and older.2–5 These rates are
equivalent to rates in myocardial infarction survivors not on
dialysis.6 The incidence of cardiac arrest is even higher
among diabetics on dialysis: 110 per 1000 patient-years in the
first year on dialysis.7
Despite the extremely high risk for cardiac arrest in the
dialysis population, there have been very few prospective
studies of SCD and risk factors associated with SCD in end-
stage renal disease (ESRD).8–11 Dialysis patients have
multiple risk factors for SCD, including atherosclerotic
CVD risk factors, a high prevalence and incidence of left
ventricular hypertrophy (LVH) with associated fibrosis,
subclinical atherosclerotic disease impacting coronary re-
serve, endothelial dysfunction, and inflammation. Further-
more, persons on dialysis are at high risk for chronic
inflammation due to the nonphysiologic nature of the
dialysis procedure, infections, vascular access, and multiple
comorbid conditions. Underreporting of comorbidities in
administrative data limits the ability to determine causal
pathways between putative risk factors and SCD. Inflamma-
tion alone or through worsening of autonomic dysfunction
and sympathetic reactivity, LVH or atherosclerosis could act
as potential triggers in the presence of an abnormal
myocardium and lead to arrhythmias and consequently an
unexpected death.12,13
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Therefore, we conducted a study to determine the
incidence of SCD in a prospective incident dialysis cohort
in the United States and to determine the association of risk
factors with SCD, in particular the influence of inflammation
on SCD.
RESULTS
Baseline characteristics of the overall Choices for Healthy
Outcomes In Caring for ESRD (CHOICE) cohort are
presented in Table 1. A total of 658 deaths occurred over
follow-up (maximum, 9.5 years) in the CHOICE cohort of
1041 participants; 146 deaths were due to SCD (22.2% of all
deaths) with a median time to SCD death of 2.9 years. There
were a total of 122 deaths among those participants who had
C-reactive protein (CRP) and interleukin-6 (IL-6) measured.
In Figure 1, the cumulative incidence of all cause mortality
was 80% over the 8 years of follow-up in the CHOICE
cohort, and by the specific causes of death, the cumulative
incidence of SCD was 20.4%, other CVD causes of death were
27.5% and other causes of death were 38.7%.
In Table 2, we present the association of serum markers of
inflammation and malnutrition with SCD. Each 0.5 g/100 ml
lower albumin was associated with a 1.42 times higher risk
for SCD in an unadjusted model. After controlling for
potential confounders such as age, race, dialysis-related
factors, and use of antihypertensives, lower albumin
remained associated with SCD (adjusted hazard ratio (Adj
HR) 1.24; 95% confidence interval, (CI) 1.04–1.47). After
additional adjustment for other inflammatory markers, the
association of a lower albumin and SCD was no longer
statistically significant. Further analyses of albumin tertiles
showed an increased risk for SCD among those with the
lowest albumin compared to the highest; however, this was
also not statistically significant, nor was the overall trend after
multivariable adjustment. In contrast, hsCRP was associated
with a 1.2 times increased risk for each logarithmic unit
higher hsCRP, even after controlling for confounders,
including other inflammatory markers. In the analysis using
tertiles of hsCRP, a similar pattern was seen. In an unadjusted
model, participants in the highest tertile of hsCRP (median
hsCRP of 1.49 mg/100 ml) were twice as likely to experience
SCD as their counterparts in the lowest tertile (median
hsCRP of 0.12 mg/100 ml). This risk was still significant after
adjustment for comorbidities, calcium–phosphorus product,
potassium, and other inflammatory markers (Adj HR 2.21;
95% CI 1.19–4.10).
The patterns of association were similar for log(IL-6). For
each unit increase in log(IL-6), the risk of SCD increased 1.4-
fold and those in the highest tertile of IL-6 (median 9.65 pg/ml)
Table 1 | Demographic and clinical characteristics of CHOICE
participants at baseline enrolled from 1995 to 1998
Characteristics
N 1041
Demographics
Age, mean (s.d.), years 57.9 (15.0)
Sex, no. (%)
Female 477 (45.8)
Male 564 (54.2)
Race, no. (%)
White 696 (66.9)
Black 294 (28.2)
Other 51 (4.9)
Clinical variables
Smoking, no. (%)
Never 385 (39.4)
Former 446 (45.7)
Current 146 (14.9)
Dialysis modality, no. (%)
Hemodialysis 767 (73.7%)
Peritoneal dialysis 274 (26.3%)
BMI 27.1 (6.7)
Systolic blood pressure, mean (s.d.), mm Hg 148.6 (18.9)
Comorbidity, no. (%)
Prevalent CVD 457 (44.0)
Diabetes 561 (54.0)
Congestive heart failure 486 (46.8)
Left ventricular hypertrophy 259 (24.9)
Index of coexistent disease score
0/1 371 (35.7)
2 360 (34.7)
3 308 (29.6)
Statin use 143 (13.7%)
ACE inhibitor use 281 (27.0%)
b-Blocker use 285 (27.4%)
Calcium channel blocker use 656 (63.0%)
Lipid levels, mean (s.d.), mg/100 ml
Total cholesterol 188.5 (49.6)
HDL 43.2 (15.1)
Calcium-phosphorus product, mean (s.d.), mg2/(100 ml)2 48.8 (12.6)
Inflammation and malnutrition
CRP, median (IQR), mg/100 mla 0.38 (0.16, 0.95)
IL-6, median (IQR), pg/mla 4.0 (2.5, 7.1)
Albumin, mean (s.d.), g/100 ml 3.6 (0.4)
ACE, angiotensin converting enzyme; BMI, body mass index; CRP, C-reactive protein;
CVD, cardiovascular disease; HDL, high-density lipoprotein; IL-6, interleukin-6; IQR,
interquartile range.
aAvailable in 867 patients.
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Figure 1 | Cumulative incidence of overall mortality and
specific causes of death (including sudden cardiac death,
other cardiovascular causes and other causes of death).
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were also at significantly higher risk for SCD (HR 2.36; 95%
CI 1.46–3.82) compared to the lowest tertile of IL-6 (median
4.04 pg/ml). This risk remained strong, although reduced,
after adjustment for comorbidities and laboratory values (Adj
HR 1.83; 95% CI 1.09–3.06). After adjusting for hsCRP and
albumin, the adjusted hazard ratio remained greater than one
but was no longer statistically significant.
Further analyses were performed to determine the risk of
SCD associated with different combinations of serum
markers of inflammation (Table 3). The greatest risk of
Table 2 | Association of serum markers of inflammation and malnutrition with SCD among the CHOICE participants
(1995–2004)
HR (95% CI)
By tertile of serum marker
Inflammatory marker Continuousa P 1 2 3 P for trend
Albumin (g/100 ml)
No. of events 145 37 50 58
Mean (range) 3.62 (1.87–4.70) 4.01 (3.83–4.60) 3.68 (3.53–3.80) 3.24 (1.87–3.50) —
Unadjusted 1.42 (1.15–1.74) 0.001 1.00 (ref.) 1.37 (0.88–2.15) 1.96 (1.27–3.03) 0.002
Model 1 1.46 (1.17–1.83) 0.001 1.00 (ref.) 1.25 (0.79–1.97) 1.88 (1.21–2.92) 0.005
Model 2 1.32 (1.01–1.71) 0.04 1.00 (ref.) 1.20 (0.72–2.01) 1.34 (0.82–2.21) 0.3
Model 3 1.30 (1.00–1.70) 0.05 1.00 (ref.) 1.22 (0.73–2.04) 1.29 (0.78–2.12) 0.3
Model 4 1.34 (1.02–1.75) 0.03 1.00 (ref.) 1.21 (0.72–2.03) 1.35 (0.81–2.23) 0.3
Model 5 1.30 (0.99–1.72) 0.06 1.00 (ref.) 1.10 (0.65–1.86) 1.25 (0.75–2.08) 0.4
hsCRP (mg/100 ml)
No. of events 122 32 39 51
Median (range) 0.38 (0.04–12.3) 0.12 (0.04–0.24) 0.38 (0.24–0.55) 1.49 (0.55–12.3) —
Unadjusted 1.27 (1.08–1.49) 0.005 1.00 (ref.) 1.24 (0.76–2.04) 2.09 (1.31–3.34) 0.002
Model 1 1.29 (1.09–1.53) 0.003 1.00 (ref.) 1.20 (0.73–1.97) 2.15 (1.33–3.46) 0.001
Model 2 1.21 (1.02–1.44) 0.03 1.00 (ref.) 1.15 (0.68–1.96) 1.97 (1.21–3.23) 0.004
Model 3 1.24 (1.04–1.47) 0.02 1.00 (ref.) 1.17 (0.69–2.01) 2.12 (1.29–3.51) 0.002
Model 4 1.24 (1.04–1.47) 0.02 1.00 (ref.) 1.14 (0.66–1.96) 2.12 (1.28–3.51) 0.002
Model 5 1.22 (0.96–1.55) 1.00 (ref.) 1.12 (0.64–1.96) 2.21 (1.19–4.10) 0.02
IL-6 (pg/ml)
No. of events 122 30 44 48
Median (range) 4.04 (0.11–66.0) 2.05 (0.11–3.02) 4.04 (3.06–5.71) 9.65 (5.73–66.0) —
Unadjusted 1.38 (1.13–1.69) 0.002 1.00 (ref.) 1.75 (1.08–2.82) 2.36 (1.46–3.82) o0.001
Model 1 1.33 (1.07–1.65) 0.01 1.00 (ref.) 1.67 (1.02–2.72) 2.16 (1.33–3.52) 0.002
Model 2 1.20 (0.96–1.51) 0.1 1.00 (ref.) 1.64 (0.99–2.72) 1.82 (1.09–3.02) 0.02
Model 3 1.21 (0.96–1.52) 0.1 1.00 (ref.) 1.76 (1.05–2.92) 1.86 (1.11–3.10) 0.02
Model 4 1.21 (0.96–1.53) 0.1 1.00 (ref.) 1.76 (1.05–2.94) 1.83 (1.09–3.06) 0.02
Model 5 0.98 (0.71–1.34) 0.9 1.00 (ref.) 1.53 (0.89–2.62) 1.41 (0.75–2.66) 0.3
CI, confidence interval; HR, hazard ratio; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6.
Model 1: age, sex, race; Model 2: model 1 + ICED, diabetes, CVD, CHF, and cholesterol; Model 3: model 2 + calcium–phosphorus product and potassium, modality; Model 4:
model 3 + ACE inhibitor, b-blocker, and calcium channel blocker use; Model 5: model 4 + other inflammatory markers (CRP and IL-6 were log-transformed for adjustment).
aFor albumin: decrease per 0.5 g/l and tertile order is reversed; for CRP: increase per 1 mg/100 ml, log-transformed; for IL-6: increase per 1 pg/ml, log-transformed. ICED index
of coexistent disease.
Table 3 | Pairwise associations of serum markers of inflammation and malnutrition with SCD among the CHOICE participants
(1995–2004)
HR (95% CI)
Tertile of serum marker
1 2 3 P
Tertile of serum marker Albumin (g/100 ml)
hsCRP (mg/100 ml) 1 1.00 (ref.) 1.96 (0.79–4.82) 2.08 (0.80–5.46)
2 1.71 (0.70–4.18) 1.07 (0.37–3.08) 3.43 (1.45–8.13) o0.001
3 2.06 (0.77–5.49) 3.51 (1.50–8.22) 4.26 (1.82–10.0)
IL-6 (pg/ml) 1 1.00 (ref.) 1.39 (0.58–3.33) 1.44 (0.51–4.02)
2 1.28 (0.50–3.25) 3.09 (1.34–7.11) 2.51 (1.07–5.91) o0.001
2.16 (0.88–5.31) 1.85 (0.73–4.69) 5.22 (2.34–11.6)
hsCRP (mg/100 ml)
IL-6 (pg/ml) 1 1.00 (ref.) 0.98 (0.43–2.21) 1.10 (0.24–4.97)
2 1.73 (0.80–3.73) 1.29 (0.62–2.68) 2.52 (1.26–5.06) o0.001
3 0.96 (0.26–3.55) 2.60 (1.25–5.42) 2.60 (1.41–4.80)
CI, confidence interval; HR, hazard ratio; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6.
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SCD was with either the highest tertile of hsCRP or IL-6. For
example, those with the highest hsCRP and those with the
lowest albumin were four times more likely to have a SCD
event compared to those with the lowest hsCRP and highest
albumin (HR 4.26; 95% CI 1.82–10.0).
Additional analyses were conducted to determine the
association of baseline CRP, IL6 and albumin with SCD
accounting for competing risk of other causes of death from
cardiovascular (CV) and non-CV causes of death. By
multivariable regression analyses controlling for demo-
graphic, clinical, dialysis and CV risk factors, we found
consistent results whether using traditional Cox models or
Cox models accounting for competing risk. Participants with
the highest tertile of CRP were at increased risk of SCD (Adj
HR 1.65; 95% CI 1.32–2.06; P for trend o0.0001) compared
to the lowest tertile of CRP. Similar analyses for IL-6 and
albumin showed that both were associated with increased risk
of SCD with a risk of 1.84 (Adj HR 95% CI 1.46–2.33; P for
trend o0.0001) and 1.69 (Adj HR 95% CI 1.35–2.12; P for
trend o0.001) for the highest IL-6 and albumin tertiles,
respectively, compared to the corresponding reference group.
Further analyses were conducted to determine the
association of baseline CRP, IL-6, and albumin with other
competing causes of death such as CV and non-CV causes of
death. By multivariable Cox regression analyses controlling
for demographic, clinical, dialysis, and CV risk factors,
participants with the highest tertile of CRP were not at
increased risk of CV death, censoring for deaths from SCD
and other causes (HR 0.98; 95% CI 0.69–1.38) compared to
the lowest tertile of CRP. Similar analyses for non-CV causes
of death demonstrated that those with the highest CRP tertile
were not at higher risk compared to the lowest tertile with the
hazard ratio crossing one (HR 1.30: 95% CI 0.97–1.74). IL-6
was associated with CV causes of death (HR 1.65; 95% CI
1.00–2.71) but not non-CV causes (HR 1.47; 95% CI
0.93–2.31). Albumin, in contrast was associated with both
CVD (HR1.71; 95% CI 1.10–2.65) and other causes of death
(HR 1.71; 95% CI 1.18–2.48) and less so with SCD.
Other factors associated with SCD using traditional Cox
models after adjusting for age, race, index of coexistent
disease (ICED), CVD, congestive heart failure (CHF),
calcium–phosphorus product, potassium, antihypertensives,
baseline modality, and all inflammatory factors included:
race, where blacks were at decreased risk for SCD compared
to whites (HR 0.49; 95% CI 0.27–0.89); and those with CHF
(HR 1.63; 95% CI 1.04–2.55); CVD (HR 1.70; 95% CI
1.09–2.67); per unit increase of 1 mEq/l of serum potassium
at baseline (HR 1.79; 95% CI 1.25–2.57); increasing ICED
(HR 1.73; 95% CI 1.31–2.29), and older age (per 10 years; HR
1.32; 95% CI 1.10–1.59) were all at higher risk for SCD.
Gender, diabetes, serum cholesterol, smoking, systolic blood
pressure, LVH, and calcium–phosphorus product X55 mg2/
(100 ml)2 were not associated with increased risk of SCD
(data not shown). Use of angiotensin converting enzyme
inhibitors, b-blockers or calcium channel blockers at baseline
was also not associated with lower risk of SCD (data not
shown). Repeat analyses taking into consideration competing
risk of other causes of death resulted in similar results except
baseline potassium and CVD were no longer statistically
significantly associated as the hazard crossed one (data not
shown).
We tabulated the SCD events defined using the National
Death Index (NDI) death certificate information and
compared the assignment of death by the Center for
Medicare and Medicaid Systems (CMS) death notification
form in Table 4. Of the 146 SCD events identified by
using the standard criteria from NDI, the primary
underlying cardiac causes were arrhythmias and myocardial
infarction. The CMS death notification classified over 75% of
those same deaths as other, unknown, missing or cardiac
arrest.
DISCUSSION
In a large prospective study of incident dialysis participants,
we show that the cumulative incidence of SCD is very high,
20.4% up to 10 years on dialysis. Inflammation and
malnutrition, as determined by low serum albumin and
higher hsCRP and IL-6 levels, was associated with a higher
risk of SCD. These associations were direct and independent
of traditional CV risk factors.
Table 4 | Assignment of cause of death by the NDI vs the CMS DN form cause for SCD eventsa
Underlying cause of death by NDI
DN cause of death MI Cardiomyopathy Arrhythmia Other Total
ASCVD/MIb 5 (9.8%) 1 (3.6%) 7 (11.3%) 1 (20.0%) 14 (9.6%)
Cardiac arrest 17 (33.3%) 7 (25.0%) 16 (25.8%) 3 (60.0%) 43 (29.5%)
Arrhythmia 3 (5.9%) 1 (3.6%) 4 (6.5%) 0 (0.0%) 8 (5.5%)
Cardiomyopathy 2 (3.9%) 3 (10.7%) 1 (1.6%) 1 (20.0%) 7 (4.8%)
Other cardiac 0 (0.0%) 1 (3.6%) 0 (0.0%) 0 (0.0%) 1 (0.7%)
Hyperkalemia 0 (0.0%) 1 (3.6%) 0 (0.0%) 0 (0.0%) 1 (0.7%)
Cerebrovascular disease 0 (0.0%) 2 (7.1%) 1 (1.6%) 0 (0.0%) 3 (2.1%)
Infection 2 (3.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (1.4%)
Other/unknown/missing 22 (43.1%) 12 (42.9%) 33 (53.2%) 0 (0.0%) 67 (45.9%)
Total 51 (100.0%) 28 (100.0%) 62 (100.0%) 5 (100.0%) 146 (100.0%)
ASCVD, atherosclerotic cardiovascular disease; DN, death notification; MI, myocardial infarction; NDI, national death index.
DN causes of death filled out by a nephrologist up to 30 days after death.
aNDI causes of death filled out by a physician, coroner or medical examiner at time of death.
bASCVD and MI.
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Despite the difference in study populations and defini-
tions, the incidence of SCD in CHOICE is approximately 37
SCD events per 1000 patient years, which is quite similar to
that seen in the hemodialysis (HEMO) study, a clinical trial
of dialysis dose among prevalent dialysis patients, with SCD
representing 25% of all deaths, and also in the 4D, a clinical
trial of statins in diabetic prevalent dialysis patients, with of
30% of all deaths from sudden death.8,14 The incidence of
SCD among ESRD is approximately 100 times greater than
that reported in the general population of approximately 0.41
per 1000 patient years in men and 0.27 per 1000 patient years
in women using similar definitions of SCD from the NDI.6
SCD is common among dialysis patients and reduction in
SCD rates would have a considerable impact on improving
survival of dialysis patients.
We also show that inflammation and malnutrition
(defined as a decreased albumin, elevated hsCRP, and IL-6
levels measured, a median of 2.5 years before SCD event
censoring) is associated with an increased risk of SCD in
dialysis patients. ESRD is an inflammatory state.15 Inflam-
mation is associated with a stepwise increased risk of
atherosclerotic cardiovascular disease in both persons with
ESRD and the general population.16–19 Inflammation could
trigger SCD through atherosclerosis or a direct effect on the
myocardium and the electrical conduction system.20 Inflam-
mation could also reflect the severity of overall burden of
cardiac disease.
CRP, in particular, was associated with the highest risk of
SCD among dialysis patients. CRP, a marker of chronic
inflammation, is positively correlated with SCD as early as 9
years before the episode of SCD, independent of traditional
risk factors for coronary disease in the general population.21
We also show that elevated CRP at baseline had a significantly
higher risk of SCD, and the findings were robust even when
accounting for competing risks from other CV or non-CV
causes of death. This increased risk may be mediated through
the development of premature atherosclerosis22–24 and
cytokine-induced plaque instability.16 In addition, CRP and
cytokines such as IL-6 have also been associated with other
arrhythmias, such as atrial fibrillation, in the absence of
coronary artery disease,13,16,20,25 raising the possibility of a
direct electrophysiological effect. Indeed, modulation of ion
channel function and production of arrhythmias by cytokines
such as platelet-activating factor have been described.26,27
Inflammation could also aggravate sympathetic tone which is
associated with poor heart rate variability especially among
patients with chronic kidney disease, diabetes, and on
dialysis.28–31 Depressed vagal tone and increased sympathetic
activity leads to tachycardia and cardiac electrical instability
which ultimately may result in SCD.
We also found that CHF was associated with SCD which is
not surprising as the risk for arrhythmias is greatest among
those with a low ejection fraction.32 Myocardial fibrosis
effects ventricular conduction and could cause delays in
repolarization leading to ventricular arrhythmias.32,33 Among
ESRD patients, LVH measured by conventional echocardio-
graphy has also been shown to be associated with increased
risk of SCD in a small cohort of Italian dialysis patients.10
LVH is common among dialysis patients with over 25–40%
having LVH at dialysis initiation.34 We did not find an
association with LVH an SCD; however, LVH data were
collected by chart abstraction and were not specifically
measured for the study.
White race was also associated with increased SCD
compared to African Americans in this dialysis population.
A similar relationship is also seen between race and incidence
of atherosclerotic CVD35 among dialysis patients. The higher
incidence of SCD and atherosclerotic CVD in whites may, in
part, account for the poorer survival of whites on dialysis
compared to blacks.35
In contrast, traditional CV risk factors such as diabetes,
smoking, blood pressure, and cholesterol were not associated
with SCD. Similar findings in the general population have
shown that hypercholesterolemia and obesity are not
consistently associated with SCD, and this probably reflects
that atherosclerosis is not the only pathway leading to
SCD.21,36 We also show no protective effect from the use of
b-blockers or calcium channel blockers at baseline entry into
the study. A recent study of survival after cardiac arrest in a
large dialysis chain demonstrated a significant protective
effect with almost 70% lower risk of death in those patients
on b-blockers 6 months after the cardiac arrest.37 b-Blockers
need to be studied prospectively to determine if long-term
use will still provide a beneficial effect in all dialysis patients.
Limitations of our study deserve mention. We were
limited by the use of the NDI and death certificate
information for our definition of SCD which may over-
estimate the incidence of SCD compared to prospective
studies.38 Nonetheless, we found similar rates of SCD
compared to those from the HEMO and 4D trials,14 and
HEMO was designed a priori to have strict definitions for
sudden death. In comparison to the classification of deaths
by the CMS death notification form, the death certificate has
to provide an underlying cause of death, and this may be
more appropriate for use when studying specific causes of
death in observational studies. In addition, we only used
baseline measurements to determine the association with
SCD and not changes in clinical parameters over time. Our
intent was to demonstrate that the measurement of
inflammatory markers at baseline has predictive value for
SCD events years later. We also could not adjust for other
dialysis-related risk factors such as intradialytic hypotension,
dialysate potassium, calcium concentrations, or time from
last dialysis which could have a significant impact on the
incidence of SCD among hemodialysis patients.39 We also did
not measure cardiac troponins which could potentially be a
sensitive marker of a vulnerable myocardium at risk of
arrhythmias.40,41 Balancing these limitations are the strengths
of the CHOICE study design which included an incident
cohort with demographic and clinical characteristics similar
to the United States Renal Data Systems and thus general-
izable to the US dialysis population.42 In addition, this cohort
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has detailed comorbid data collected at baseline and abstracted
by trained nurses, a serum repository that allowed for
measurement of analytes, which have not been typically
available in other cohorts and prospective follow-up to 10 years.
SCD was common among participants in CHOICE, with
approximately 22% of all deaths attributed to SCD.
Inflammation and malnutrition significantly increases the
risk of SCD independent of traditional risk factors, and
baseline hsCRP measurements at dialysis initiation could
serve as prognostic factor for SCD. Further studies are needed
to prospectively study SCD and association of dialysis-related
risk factors in order to improve the survival of persons on
dialysis.
METHODS
Study design and population
The CHOICE study is a national prospective cohort study of 1041
patients who recently initiated dialysis and were aged 19–95 years
from 81 dialysis clinics associated with Dialysis Clinic, Incorporated
(DCI, Nashville, TN, USA; n¼ 923 from 79 clinics), New Haven
Chronic Ambulatory Peritoneal Dialysis (New Haven, CT, USA;
n¼ 86), or Saint Raphael’s Hospital (New Haven, CT, USA; n¼ 32),
described previously.43 Participants were enrolled from October
1995 to June 1998 a median of 45 days after initiation of dialysis
(98% within 4.0 months). Blood was drawn and stored in a
specimen bank only for participants enrolled at the DCI clinics, of
whom 867 (94%; 867/923) had inflammation profiles measured.
The study was approved by the Institutional Review Boards at Johns
Hopkins University, and the associated clinical sites, and partici-
pants provided written informed consent.
Measurements
Baseline demographic and clinical data were obtained from hospital
and clinic records and self-administered participant questionnaires
at the time of enrollment. Prevalent CVD was defined as medical
record documentation of coronary artery disease, cerebrovascular
disease, and peripheral vascular disease. CHF was defined as
diagnosis of any CHF or history of pulmonary edema or CHF
requiring medications in the previous year before dialysis initiation,
multiple episodes of hypotension during hemodialysis related to
cardiomyopathy, or more than two hospitalizations for CHF in the
year before dialysis initiation. LVH was defined by LVH on
electrocardiogram or echocardiogram. The presence of CVD and
other comorbidities was assessed by trained nurses according to
medical records and clinic staff reports by using the ICED, a
standardized and validated composite four-level scale tested in
multiple studies.44 Clinical variables at dialysis initiation included
age, gender, race (black, white, and other), former and current
smoking, dialysis modality (hemodialysis or peritoneal dialysis),
body mass index (kg/m2), use of statins and antihypertensive
medications (angiotensin converting enzyme inhibitors, b-blockers,
calcium channel blockers). Clinical parameters that were assessed as
continuous variables were averaged over the 3 months following
study enrollment and included predialysis systolic blood pressure,
total serum cholesterol, albumin, calcium–phosphorus product
(mg2/(100 ml)2), and predialysis potassium (mEq/l). Nonfasting
blood specimens were drawn before a dialysis treatment at a median
of 5.0 months from the initiation of dialysis (95% within 8.7
months), shipped overnight to a central laboratory, and stored at
80 1C for measurement of CRP and IL-6. Serum albumin levels
from the core DCI laboratory were measured by using the
Bromocresol Green method (CV, 1.1%). Serum high-sensitivity
(hs)CRP, an acute phase protein, was measured by using a
colorimetric competitive enzyme-linked immunosorbent assay
(CV, 8.9%). IL-6, a proinflammatory cytokine, was measured in
serum by an ultrasensitive enzyme-linked immunosorbent assay
method (CV, 7%).
Outcome ascertainment
Death was ascertained using data from the NDI, which is compiled
from death certificates processed in state vital statistics offices and
then sent to the National Center for Health Statistics for entry into a
national mortality database file. Causes of death on the death
certificate are reported by a physician, medical examiner, or coroner.
SCD was defined as a death that was reported as occurring out of
hospital with an underlying cause of death reported as cardiac
disease with the following codes: ICD-9 390–398, 402, or 404–429;
and ICD-10, I00–I09, I11, I13, and I20–I51. We used standard
definitions defining SCD mortality from the US vital statistics
mortality data compiled by the National Center for Health Statistics
at the Centers for Disease Control and Prevention.6,45 In addition,
we excluded deaths if hyperkalemia, sepsis, or malignancy was listed
as a concomitant cause of death or if death occurred in a hospice.
Deaths occurring in a hospice may occur through arrhythmic
mechanisms; however, these deaths are not unexpected and thus,
were excluded due to our a priori definition of SCD. Place of death
was determined using data from the CMS death notification form
from the United States Renal Data Systems.
We also compared SCD events using death certificate informa-
tion from NDI and the assigned cause of death from the CMS death
notification form which is filled out by the primary nephrologist at
the dialysis unit and can be filled out up to one month after the
death occurred.
Data analysis
Baseline characteristics are presented using descriptive statistics. All
inflammatory markers were analyzed both as tertiles and as
continuous variables. CRP and IL-6 were not normally distributed
and were log transformed for the analyses. Traditional Kaplan–Meier
survival analytical methods may overestimate the cumulative
incidence as it does not take into account competing causes of
death.46,47 To consider competing risks from other causes of death
such as other causes of CVD and nonCVDs, survival curves were
generated using competing risk analytic techniques.48 In Cox
proportional hazards models, follow-up time was defined as the
period from initiation of dialysis to SCD, with staggered entry to
allow for the various times at which different subjects had their
inflammatory markers measured.49 Individuals were censored at
time of death due to other causes (n¼ 512, renal transplant
(n¼ 260), or end of follow-up on 31 December 2004 (n¼ 123).
Relative hazards and 95% CIs from multivariable Cox proportional
hazards models were used to examine the independent association
between baseline inflammatory risk factors (baseline serum
albumin, IL-6, and hsCRP levels) and SCD. Models were adjusted
for demographic factors, traditional CVD risk factors, dialysis-
related factors (calcium–phosphorus and potassium), presence of
cardiomyopathy, medications, and ICED comorbidity index. To
account for potential confounding by clinic, all the analyses were
clustered by clinic. Additional Cox models were also constructed
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accounting for competing risk from CV and non-CV causes of
deaths to determine the association of albumin, hsCRP and IL-6
with SCD using methods by Lunn and McNeil.47 For all survival
analyses, the proportionality assumption of the Cox model was
confirmed by test of Schoenfeld residuals. We also tabulated
underlying causes of SCD by the NDI and compared the cause of
death defined by the CMS death notification form.
All analyses were performed using STATA Intercooled statistical
software (version 8.2). Po0.05 was considered significant.
DISCLOSURE
The authors have no financial interests to disclose.
ACKNOWLEDGMENTS
We thank the patients, staff, laboratory, and physicians of Dialysis
Clinic Inc. (DCI), New Haven CAPD and St Raphael’s Hospital for their
participation in the CHOICE Study.CHOICE was supported by RO1-HL-
62985 (National Heart, Lung, and Blood Institute (NHLBI) from 9/00 to
6/06) and RO1-DK-59616 (National Institute of Diabetes & Digestive &
Kidney Diseases (NIDDK) from 9/00 to 6/07). Dr Kao and Dr Parekh
were supported by 1UO1-DK-57304-01 and 1 R01 DK070657-01. Dr
Coresh was supported in part as an American Heart Association
established investigator (01-4019-7N). Dr Powe was supported in part
by K24-DK-02643 (NIDDK). Dr Klag was supported by K24-DK-02856
(NIDDK).
REFERENCES
1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular
disease in chronic renal failure. Am J Kidney Dis 1998; 32: S112–S119.
2. U.S. Renal Data System, USRDS 2004 Annual Data Report. Atlas of End-
Stage Renal Disease in the United States. National Institutes of Health,
National Institute of Diabetes and Digestive and Kidney Diseases:
Bethesda, MD, USA, 2004.
3. Herzog CA. Sudden cardiac death and acute myocardial infarction in
dialysis patients: perspectives of a cardiologist. Semin Nephrol 2005; 25:
363–366.
4. Herzog CA. Can we prevent sudden cardiac death in dialysis patients?
Clin J Am Soc Nephrol 2007; 2: 410–412.
5. Herzog CA, Li S, Weinhandl ED et al. Survival of dialysis patients after
cardiac arrest and the impact of implantable cardioverter defibrillators.
Kidney Int 2005; 68: 818–825.
6. Zheng ZJ, Croft JB, Giles WH et al. Sudden cardiac death in the United
States, 1989 to 1998. Circulation 2001; 104: 2158–2163.
7. Herzog CA. Cardiac arrest in dialysis patients: approaches to alter an
abysmal outcome. Kidney Int Suppl 2003; 84: S197–S200.
8. Cheung AK, Sarnak MJ, Yan G et al. Cardiac diseases in maintenance
hemodialysis patients: results of the HEMO Study. Kidney Int 2004; 65:
2380–2389.
9. Karnik JA, Young BS, Lew NL et al. Cardiac arrest and sudden death in
dialysis units. Kidney Int 2001; 60: 350–357.
10. Paoletti E, Specchia C, Di Maio G et al. The worsening of left ventricular
hypertrophy is the strongest predictor of sudden cardiac death in
haemodialysis patients: a 10 year survey. Nephrol Dial Transplant 2004;
19: 1829–1834.
11. Takeda K, Harada A, Okuda S et al. Sudden death in chronic dialysis
patients. Nephrol Dial Transplant 1997; 12: 952–955.
12. Shehab AM, MacFadyen RJ, McLaren M et al. Sudden unexpected death
in heart failure may be preceded by short term, intraindividual increases
in inflammation and in autonomic dysfunction: a pilot study. Heart 2004;
90: 1263–1268.
13. Mukamal KJ, Tolstrup JS, Friberg J et al. Fibrinogen and albumin levels
and risk of atrial fibrillation in men and women (the Copenhagen City
Heart Study). Am J Cardiol 2006; 98: 75–81.
14. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2
diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353:
238–248.
15. Stenvinkel P. Inflammatory and atherosclerotic interactions in the
depleted uremic patient. Blood Purif 2001; 19: 53–61.
16. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global
risk assessment in the primary prevention of cardiovascular disease.
Circulation 2001; 103: 1813–1818.
17. Yeun JY, Kaysen GA. C-reactive protein, oxidative stress, homocysteine,
and troponin as inflammatory and metabolic predictors of atherosclerosis
in ESRD. Curr Opin Nephrol Hypertens 2000; 9: 621–630.
18. Wang TJ, Larson MG, Levy D et al. C-reactive protein is associated with
subclinical epicardial coronary calcification in men and women: the
Framingham Heart Study. Circulation 2002; 106: 1189–1191.
19. Arici M, Walls J. End-stage renal disease, atherosclerosis, and
cardiovascular mortality: is C-reactive protein the missing link? Kidney Int
2001; 59: 407–414.
20. Dernellis J, Panaretou M. C-reactive protein and paroxysmal atrial
fibrillation: evidence of the implication of an inflammatory process in
paroxysmal atrial fibrillation. Acta Cardiol 2001; 56: 375–380.
21. Albert CM, Ma J, Rifai N et al. Prospective study of C-reactive protein,
homocysteine, and plasma lipid levels as predictors of sudden cardiac
death. Circulation 2002; 105: 2595–2599.
22. Ridker PM, Buring JE, Shih J et al. Prospective study of C-reactive protein
and the risk of future cardiovascular events among apparently healthy
women. Circulation 1998; 98: 731–733.
23. Ridker PM, Cushman M, Stampfer MJ et al. Plasma concentration of
C-reactive protein and risk of developing peripheral vascular disease.
Circulation 1998; 97: 425–428.
24. Ridker PM, Haughie P. Prospective studies of C-reactive protein as
a risk factor for cardiovascular disease. J Investig Med 1998; 46:
391–395.
25. Chung MK, Martin DO, Sprecher D et al. C-reactive protein elevation in
patients with atrial arrhythmias: inflammatory mechanisms and
persistence of atrial fibrillation. Circulation 2001; 104: 2886–2891.
26. Hoffman BF, Feinmark SJ, Guo SD. Electrophysiologic effects of
interactions between activated canine neutrophils and cardiac myocytes.
J Cardiovasc Electrophysiol 1997; 8: 679–687.
27. Hoffman BF, Guo SD, Feinmark SJ. Arrhythmias caused by platelet
activating factor. J Cardiovasc Electrophysiol 1996; 7: 120–133.
28. Rubinger D, Revis N, Pollak A et al. Predictors of haemodynamic instability
and heart rate variability during haemodialysis. Nephrol Dial Transplant
2004; 19: 2053–2060.
29. Dursun B, Demircioglu F, Varan HI et al. Effects of different dialysis
modalities on cardiac autonomic dysfunctions in end-stage renal disease
patients: one year prospective study. Ren Fail 2004; 26: 35–38.
30. Karayaylali I, San M, Kudaiberdieva G et al. Heart rate variability, left
ventricular functions, and cardiac autonomic neuropathy in patients
undergoing chronic hemodialysis. Ren Fail 2003; 25: 845–853.
31. Fukuta H, Hayano J, Ishihara S et al. Prognostic value of nonlinear heart
rate dynamics in hemodialysis patients with coronary artery disease.
Kidney Int 2003; 64: 641–648.
32. Naghavi M, Libby P, Falk E et al. From vulnerable plaque to vulnerable
patient: a call for new definitions and risk assessment strategies: part II.
Circulation 2003; 108: 1772–1778.
33. Myerburg RJ. Sudden cardiac death: exploring the limits of our
knowledge. J Cardiovasc Electrophysiol 2001; 12: 369–381.
34. Foley RN. Clinical epidemiology of cardiac disease in dialysis patients: left
ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin
Dial 2003; 16: 111–117.
35. Parekh RS, Zhang L, Fivush BA et al. Incidence of atherosclerosis by race
in the dialysis morbidity and mortality study: a sample of the US ESRD
population. J Am Soc Nephrol 2005; 16: 1420–1426.
36. Albert CM, Chae CU, Grodstein F et al. Prospective study of sudden
cardiac death among women in the United States. Circulation 2003; 107:
2096–2101.
37. Pun PH, Lehrich RW, Smith SR et al. Predictors of survival after cardiac
arrest in outpatient hemodialysis clinics. Clin J Am Soc Nephrol 2007; 2:
491–500.
38. Anderson RN, Minino AM, Hoyert DL et al. Comparability of cause of
death between ICD-9 and ICD-10: preliminary estimates. Natl Vital Stat
Rep 2001; 49: 1–32.
39. Bleyer AJ, Hartman J, Brannon PC et al. Characteristics of sudden death in
hemodialysis patients. Kidney Int 2006; 69: 2268–2273.
40. Fonarow GC, Horwich TB. Combining natriuretic peptides and necrosis
markers in determining prognosis in heart failure. Rev Cardiovasc Med
2003; 4(Suppl 4): S20–S28.
41. Iliou MC, Fumeron C, Benoit MO et al. Prognostic value of cardiac markers
in ESRD: Chronic Hemodialysis and New Cardiac Markers Evaluation
(CHANCE) study. Am J Kidney Dis 2003; 42: 513–523.
42. Longenecker JC, Coresh J, Klag MJ et al. Validation of comorbid
conditions on the end-stage renal disease medical evidence report: the
CHOICE study. Choices for Healthy Outcomes in Caring for ESRD. J Am
Soc Nephrol 2000; 11: 520–529.
Kidney International (2008) 74, 1335–1342 1341
RS Parekh et al.: Incidence of sudden cardiac death o r i g i n a l a r t i c l e
43. Longenecker JC, Coresh J, Powe NR et al. Traditional cardiovascular
disease risk factors in dialysis patients compared with the general
population: the CHOICE Study. J Am Soc Nephrol 2002; 13: 1918–1927.
44. Miskulin DC, Meyer KB, Athienites NV et al. Comorbidity and other factors
associated with modality selection in incident dialysis patients: the
CHOICE Study. Choices for Healthy Outcomes in Caring for End-Stage
Renal Disease. Am J Kidney Dis 2002; 39: 324–336.
45. Zheng Z, Croft JB, Giles WH et al. State-specific mortality from sudden
cardiac death: United States, 1999. MMWR Morb Mortal Wkly Rep 2002;
51: 123–126.
46. Prentice RL, Kalbfleisch JD, Peterson Jr AV et al. The analysis of failure
times in the presence of competing risks. Biometrics 1978; 34: 541–554.
47. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics
1995; 51: 524–532.
48. Choudhury JB. Non-parametric confidence interval estimation for
competing risks analysis: application to contraceptive data. Stat Med
2002; 21: 1129–1144.
49. Liu Y, Coresh J, Eustace JA et al. Association between cholesterol level
and mortality in dialysis patients: role of inflammation and malnutrition.
JAMA 2004; 291: 451–459.
1342 Kidney International (2008) 74, 1335–1342
o r i g i n a l a r t i c l e RS Parekh et al.: Incidence of sudden cardiac death
